By Colin Kellaher
Neumora Therapeutics shares edged lower in their trading debut Friday after the clinical-stage biopharmaceutical company’s initial public offering was priced at the midpoint of expectations.
The Watertown, Mass., company sold about of 14.7 million shares at $17 apiece, compared with an expected price range of $16 to $18.
Neumora shares were recently changing hands at $16.66, down 2%, after opening at $16.50.
The company said it granted the underwriters an option to buy an additional 2.21 million shares.
Write to Colin Kellaher at [email protected]
Read the full article here
